Association between topiramate and zonisamide use during pregnancy and low birth weight

Obstetrics and Gynecology

Volumn 123, Issue 1, 2014, Pages 21-28

  Hernández Díaz, Sonia ^a,b,c,d   Mittendorf, Robert ^a,b,c,d   Smith, Caitlin R ^a,b,c,d   Hauser, W Allen ^a,b,c,d   Yerby, Mark ^a,b,c,d   Holmes, Lewis B ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c Columbia University ^*  (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; TOPIRAMATE; ZONISAMIDE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; FETUS GROWTH; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MONOTHERAPY; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PUERPERIUM; RISK FACTOR; SMALL FOR DATE INFANT; TELEPHONE INTERVIEW;

ADULT; ANTICONVULSANTS; BIRTH WEIGHT; COHORT STUDIES; FEMALE; FRUCTOSE; HUMANS; ISOXAZOLES; PREGNANCY; REGISTRIES;

EID: 84893646877     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000018     Document Type: Article

References (27)

1. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramatetreated epilepsy. Obes Res 2003;11:556-62.
2. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11: 722-33.
3. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the longterm efficacy and safety of topiramate in the treatment of obese subjects. International journal of obesity and related metabolic disorders. Int J Obes Relat Metab Disord 2004;28:1399-410.
4. Tata A, Kockler D. Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother 2006;40:1993-7.
5. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther 2010;8:1777-801.
6. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308.
7. VIVUS, Inc. VI-0521 (QNEXA®) advisory committee briefing document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292317.pdf. 2012. Retrieved August 20, 2012.
8. Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.e1-7.
9. Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9.
10. Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, et al. Topiramate in pregnancy. Preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71:272-6.
11. Sheth RD, Montouris G. Metabolic effects of AEDs: impact on body weight, lipids and glucose metabolism. Int Rev Neurobiol 2008;83:329-46.
12. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. In: Joost HG, editor. Appetite control, handbook of experimental pharmacology. Berlin, Heidelberg (Germany): Springer-Verlag; 2012. p. 433-66.
13. Gadde KM, Franciscy DM, Wagner HR II, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-5.
14. McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004;65:50-6.
15. Gadde KM, Kopping MF, Wagner HR, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012;172:1557-64.
16. Full prescribing information for Topamax®. Available at: http://www.topamax.com/sites/default/files/topamax.pdf. Retrieved August 20, 2012.
17. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 2008; 25:388-9.
18. Holmes L, Wyszynski D, Lieberman E. The antiepileptic drug pregnancy registry: a six year experience. Arch Neurol 2004; 61:673-8.
19. Wyszynski D, Nambisan M, Surve T, Alsdorf R, Smith C, Holmes L; Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-5.
20. Holmes LB, Baldwin E, Habecker E, Glassman L, Wong S, Wyszynsky DF. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152-8.
21. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003;3:6.
22. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16:961-6.
23. Luyckx V, Bertram J, Brenner B. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 2013;382:273-83.
24. La Merrill M, Stein CR, Landrigan P, Engel SM, Savitz DA. Prepregnancy body mass index, smoking during pregnancy, and infant birth weight. Ann Epidemiol 2011;21: 413-20.
25. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev 2007;28:219-51.
26. Goetzinger KR, Cahill AG, Macones GA, Odibo AO. The relationship between maternal body mass index and tobacco use on small-for-gestational-age infants. Am J Perinatol 2012;29:153-8.
27. Dugan K, Margulis AV, Hernandez-Diaz S. Topiramate for weight loss. Pharmacoepidemiol Drug Saf 2011;20:S1-382.